Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil

Transplantation

Volumn 82, Issue 1, 2006, Pages 113-118

  Devyatko, Elena ^a   Zuckermann, Andreas ^a   Bohdjalian, Arthur ^a   Roedler, Suzanne ^a   Dunkler, Daniela ^a   Grimm, Michael ^a   Weigel, Guenter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Heart transplantation; Immunosuppression; Mechanism of action; Mycophenolate mofetil

Indexed keywords

ADENOSINE TRIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE NUCLEOTIDE; AZATHIOPRINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; NUCLEOTIDE METABOLISM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PURINE METABOLISM; CLINICAL TRIAL; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; AZATHIOPRINE; ENZYME ACTIVATION; FEMALE; GUANOSINE TRIPHOSPHATE; HEART TRANSPLANTATION; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PURINE NUCLEOTIDES;

EID: 33747460712     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000225759.54343.23     Document Type: Article

References (23)

1. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66(4): 507.
2. Zuckermann A, Ploner M, Keziban U, et al. Benefit of mycophenolate- mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation. J Heart Lung Transplant 2001; 20(2): 163.
3. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76(6): 984.
4. Klupp J, Dambrin C, Hibi K, et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts.Am J Transplant 2003; 3(7): 817.
5. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004; 77(11): 1661.
6. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
7. Wu JC. The mechanism of action of mycophenolate mofetil. Perspect Drug Discovery Design 1994; 2: 185.
8. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17(6): 681.
9. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25(2): 137.
10. Shaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit 2002; 24(1): 68.
11. Devyatko E, Ploner M, Zuckermann A et al. Value of mycophenolic acid trough level monitoring after lung transplantation. Transplant Proc 2002; 34(5): 1881.
12. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25(5): 609.
13. Budde K, Glander P, Bauer S et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38(11): 1213.
14. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68(2): 261.
15. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996; 62(5): 666.
16. Millan O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000; 46(9): 1376.
17. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65(6): 640.
18. Weigel G, Griesmacher A, Zuckermann AO, et al. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001; 69(3): 137.
19. Griesmacher A, Weigel G, Seebacher G, Muller MM. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997; 43(12): 2312.
20. Daxecker H, Raab M, Muller MM. Influence of mycophenolic acid on inosine 5′-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. Clin Chim Acta 2002; 318(1-2): 71.
21. Seebecher G, Weigel G, Wolner E, et al. A simple and cost saving HPLC method for the determination of mycophenolic acid and its glucuronidated metabolite in human plasma after heart transplantation. Clin Chem Lab Med 1999; 37: 409.
22. Bland JM, Altmann DG. Calculating correlation coefficient with repeated observations. Part 1: correlation with subjects. BMJ 1995; 310: 446.
23. Vogt MH, Stet EH, De Abreu RA, et al. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993; 1181(2): 189.